BAY 1003803

Drug Profile

BAY 1003803

Alternative Names: BAY-1003803

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis

Most Recent Events

  • 31 Mar 2017 Bayer completes a phase I trial in Psoriasis in Germany (Topical, Cream) (Topical, Ointment) (NCT02940002)
  • 19 Oct 2016 Bayer plans a phase I trial for Psoriasis (In volunteers) in Germany (NCT02936492)
  • 12 Oct 2016 Phase-I clinical trials in Psoriasis in Germany (Topical, Cream) (NCT02940002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top